MAY 7, 2026 · REGULATORY LABEL UPDATE
FDA supplemental approval: Risperidone (Labeling)
U.S. Food and Drug Administration
FDA supplemental approval of labeling changes for risperidone tablets; this is a regulatory action record, not a clinical trial, and does not report efficacy or safety trial outcomes.
Reported
Approval date2026-05-07
Dosage strengths approved0.25 mg, 0.5 mg, 1 mg, 3 mg tablets